09.13.13
Alameda, Calif.-based BioTime Inc., a 23-year-old biotechnology company that makes products in the field of regenerative medicine, recently expanded its senior management team with the appointment of Lesley Stolz, Ph.D., as executive vice president of corporate development. Stolz has more than 18 years of life science industry experience in corporate and business development.
“Lesley brings a strong background in corporate and business development to BioTime, including more than 20 successfully concluded technology and therapeutics partnering and financing transactions in the life sciences,” said Michael D. West, Ph.D., BioTime’s CEO. “She will have primary responsibility for interactions with both investors and corporate partners. Additionally, she will focus on identifying and implementing strategic initiatives for BioTime and its subsidiaries. As we complete the building of our leading technology and intellectual property position in regenerative medicine and begin clinical trials with multiple products, Lesley will work with corporate partners and investors on the next stage of BioTime’s development. As with previous new technologies in the history of biotechnology, it is likely that many regenerative medicine therapeutics will be developed through partnerships between biotechnology companies and commercial therapeutics companies.”
Prior to joining BioTime, Stolz was vice president of business development for Sutro Biopharma Inc., a company focused on protein therapeutics, where she was responsible for all corporate partnering activities as well as business strategy development and implementation, and raising capital. Earlier in her career, Stolz worked with Sunesis Pharmaceuticals Inc., Aerovance Inc., and GPC Biotech AG in Munich, Germany. She holds a Ph.D. in chemistry from the University of Rochester, and a bachelor of science degree in chemistry from the University of Virginia. She conducted postdoctoral research at the Harvard Medical School Department of Biochemistry and Molecular Pharmacology.
“Lesley brings a strong background in corporate and business development to BioTime, including more than 20 successfully concluded technology and therapeutics partnering and financing transactions in the life sciences,” said Michael D. West, Ph.D., BioTime’s CEO. “She will have primary responsibility for interactions with both investors and corporate partners. Additionally, she will focus on identifying and implementing strategic initiatives for BioTime and its subsidiaries. As we complete the building of our leading technology and intellectual property position in regenerative medicine and begin clinical trials with multiple products, Lesley will work with corporate partners and investors on the next stage of BioTime’s development. As with previous new technologies in the history of biotechnology, it is likely that many regenerative medicine therapeutics will be developed through partnerships between biotechnology companies and commercial therapeutics companies.”
Prior to joining BioTime, Stolz was vice president of business development for Sutro Biopharma Inc., a company focused on protein therapeutics, where she was responsible for all corporate partnering activities as well as business strategy development and implementation, and raising capital. Earlier in her career, Stolz worked with Sunesis Pharmaceuticals Inc., Aerovance Inc., and GPC Biotech AG in Munich, Germany. She holds a Ph.D. in chemistry from the University of Rochester, and a bachelor of science degree in chemistry from the University of Virginia. She conducted postdoctoral research at the Harvard Medical School Department of Biochemistry and Molecular Pharmacology.